“Epirubicin and Docetaxel As Neoadjuvant Treatment of Hormone Receptor Positive, HER-2 Negative Breast Cancer: Results from Two Successive Phase II Studies”. 2013. Radiology and Oncology 47 (1). https://radioloncol.com/index.php/ro/article/view/728.